CERGAS - Centre for Research on Health and Social Care Management, SDA Bocconi School of Management, Milano, Lombardia, Italy
CERGAS - Centre for Research on Health and Social Care Management, SDA Bocconi School of Management, Milano, Lombardia, Italy.
Eur J Hosp Pharm. 2022 Nov;29(6):346-352. doi: 10.1136/ejhpharm-2020-002465. Epub 2021 Mar 3.
Early rescue surfactant therapy using less invasive surfactant administration (LISA) can reduce the need for mechanical ventilation and avoid complications in preterm infants with respiratory distress syndrome. The purpose of this study was to estimate the budget impact of LISA compared with management based on continuous positive airway pressure (CPAP) alone and rescue surfactant therapy in case of CPAP failure.
A budget impact model was built comparing LISA with CPAP alone in order to estimate the potential resource consumption and budget impact from the perspective of the National Health Service in England. A literature review was conducted to populate the model. Deterministic and probabilistic sensitivity analyses were conducted to characterise the existing uncertainty and to explore the contribution of individual model parameters to the overall budget impact.
Early rescue with LISA is expected to reduce resource consumption and costs compared with conservative therapy based on CPAP alone for preterm infants born at 25-32 weeks gestation. Savings are higher for preterm infants of 25-28 weeks (expected budget impact -£5146 per case, 95% credible interval (CrI) -£22 403 to £13, probability of being cost saving 97.4%) than for preterm infants of 29-32 weeks (-£176, 95% CrI -£4279 to £339, probability of being cost saving 85%). The impact of bronchopulmonary dysplasia (BPD) and intraventricular haemorrhage on resource consumption and the expected reduction in the incidence of BPD with LISA are the most influential parameters on the budget.
Early rescue with LISA used in preterm infants with respiratory distress syndrome and fraction of inspired oxygen ≥0.3 is expected to be cost saving compared with management based on CPAP alone, particularly in those born at 25-28 weeks gestation.
使用微创气管内表面活性物质给药(LISA)的早期救援表面活性剂治疗可以减少有呼吸窘迫综合征的早产儿对机械通气的需求,并避免并发症。本研究的目的是估计 LISA 与单独持续气道正压通气(CPAP)管理以及 CPAP 失败时的救援表面活性剂治疗相比的预算影响。
建立了一个预算影响模型,将 LISA 与单独 CPAP 进行比较,以便从英国国家卫生服务的角度估计潜在资源消耗和预算影响。进行文献回顾以填充模型。进行确定性和概率敏感性分析以描述现有不确定性,并探讨模型参数对总体预算影响的贡献。
与单独 CPAP 保守治疗相比,预计 LISA 早期救援可减少 25-32 周出生的早产儿的资源消耗和成本。25-28 周早产儿的节省额更高(预期预算影响-每例 5146 英镑,95%可信区间(CrI)-22403 至 13000 英镑,成本节约概率 97.4%),而 29-32 周早产儿的节省额较低(-176 英镑,95% CrI -4279 至 339 英镑,成本节约概率 85%)。支气管肺发育不良(BPD)和脑室内出血对资源消耗的影响以及 LISA 预期降低 BPD 的发生率是对预算影响最大的参数。
与单独 CPAP 管理相比,在有呼吸窘迫综合征和吸入氧分数≥0.3 的早产儿中使用 LISA 的早期救援预计将节省成本,尤其是在 25-28 周出生的早产儿中。